(Bloomberg) — Martin Shkreli, the hip-hop-loving, short-selling, drug-price-inflating, 32-year-old biotech chief executive, seemed to be daring the world to come after him. The world, or at least the U.S. Department of Justice, has now obliged.
As Bloomberg News reported, federal agents arrested Shkreli early this morning at his Manhattan home on charges of securities fraud.
The allegations against the controversial executive don’t have to do with his most notorious caper—namely, raising the price of a life-saving medication from $13.50 a pill to $750. Instead, the federal case against Shkreli involves accusations that he illegally fleeced a biotech company he started in 2011 called Retrophin. Shkreli allegedly used Retrophin stock to pay off investors he owed money for losses they’d suffered at a separate hedge fund he ran.
Shkreli loves to provoke outrage, as his insult-filled Twitter feed amply illustrates. Beginning more than a decade ago, in his early 20s, he made enemies in the biotech industry by “shorting,” or betting against, the shares of small drugmakers. Then, with Retrophin, he tempted the fates by turning around and joining the very industry he’d spent years attacking. He made the ultimate long bet, and seemed for a time to be succeeding, as Retrophin grew in market cap and made a lot of money for Shkreli and his investors. Eventually, though, he was ousted by his board and sued by directors who accused him of playing what amounted to a shell game with the company’s stock and cash.
See also: Hillary Clinton fixes sights on ripe target: prescription drug prices
When Shkreli was at his peak at Retrophin, before the Federal Bureau of Investigation began sniffing around, Bloomberg Businessweek profiled the wunderkind, posing the question of whether the self-described wheeler-dealer had “undergone a conversion, as he claims, to creating value and saving lives. Or is he using what he learned about biotech—a field notorious for empty promises—to game the field?”